Project description DEENESFRITPL Unravelling mitochondria's role in glioblastoma Cancer cells display an altered metabolism as a result of genetic mutations, changes in the tumour microenvironment, and interactions with other cell types. Emerging evidence indicates that cancer cells incorporate mitochondrial genes or whole mitochondria to maintain their bioenergetic state. Funded by the Marie Skłodowska-Curie Actions programme, the MITIG project aims to understand how this process affects metabolism and tumour development of glioblastoma multiforme (GBM), a common and aggressive brain tumour in adults. By studying mitochondrial import, MITIG hopes to find new targets for therapy and advance our knowledge of cancer metabolism, growth, and resistance to treatment. The project includes a training program and collaboration with experts to promote research and public engagement. Show the project objective Hide the project objective Objective Glioblastoma multiforme (GBM) represents the most frequent and aggressive type of primary brain tumours in adults. Despite significant advances, current treatments involving resection and radiation/chemotherapy only partially mitigate the dire prognosis for GBM, hence avidly seeking for novel therapeutic approaches against a disease with still no virtual cure and a high socio-economic impact in the EU.A common feature in GBM, as in many other cancers, is their escape to the retrograde signalling and metabolic regulation exerted by mitochondria -the bioenergetic central of the cell. Modulation of mitochondrial function thus represents a primary target to rewire metabolism and counteract tumour progression and chemotherapy resistance. MITIG capitalizes on the recent reported ability of gliomas to import exogenous mitochondria, either isolated or transferred from surrounding neural cells in the brain, to foster tumour development and malignancy in vivo. MITIG will target both paths for mitochondrial importation to remodel organelle content and address i) how incorporation of exogenous mitochondria impacts respiratory metabolism in GBM cells and iii) the relevance of this metabolic rewiring for tumour development in vivo. Departing from mitochondrial acquisition as a novel tool to redefine respiration and metabolism in cancer, MITIG will develop a comprehensive training program fostering MSCA and EU values on research, dissemination and public engagement. An international network of experts will support the training in the intersectorial, multidisciplinary facets of MITIG. In sum, while paving the way for a promising novel biomedical field, MITIG aims at providing novel therapeutic targets and overcoming long lasting questions on respiratory metabolism in GBM and cancer as a whole. Fields of science medical and health sciencesclinical medicineoncology Programme(s) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Topic(s) MSCA-IF-2017 - Individual Fellowships Call for proposal H2020-MSCA-IF-2017 See other projects for this call Funding Scheme MSCA-IF-EF-ST - Standard EF Coordinator UNIVERSIDAD DE SALAMANCA Net EU contribution € 158 121,60 Address Calle patio de escuelas 1 37008 Salamanca Spain See on map Region Centro (ES) Castilla y León Salamanca Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00
